Definition
Atomoxetine is a highly selective centrally acting norepinephrine reuptake inhibitor (SNRI), licensed for the treatment of attention-deficit hyperactivity disorder (ADHD) in USA, United Kingdom, and elsewhere. Atomoxetine is a white solid intended for oral administration.
Pharmacological Properties
Pharmacokinetics
Following oral ingestion with or without food, atomoxetine is rapidly absorbed with peak plasma levels occurring at approximately 1–1.5 h (Sauer et al. 2005). With regular dosing, steady-state concentrations are obtained by day 10, with trough plasma concentrations of ~30–40°ng/mL. The metabolism of atomoxetine is dependent primarily on the hepatic cytochrome P450(CP450) system, which is highly polymorphic such that individuals can be classified into extensive metabolizers (EMs) or poor metabolizers...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bymaster FP et al (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5):699–711
Chamberlain SR et al (2006) Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311(5762):861–863
Chamberlain SR et al (2007) Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 62:977–984
Chamberlain SR et al (2009) Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry 65(7):550–555
Cheng JY et al (2007) Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 194(2):197–209
Cottrell S et al (2008) A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health 11(3):376–388
Faraone SV et al (2005) Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct 1:16
Robinson ES et al (2008) Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 33(5):1028–1037
Sauer JM, Ring BJ, Witcher JW (2005) Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44(6):571–590
Spencer T et al (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155(5):693–695
Trzepacz PT et al (2008) CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol 18(2):79–86
Virani A (2005) Perspectives in psychopharmacology: spotlight on atomoxetine. Can Child Adolesc Psychiatr Rev 14(4):96–98
Wee S, Woolverton WL (2004) Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend 75(3):271–276
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Chamberlain, S.R., Sahakian, B.J. (2010). Atomoxetine. In: Stolerman, I.P. (eds) Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68706-1_35
Download citation
DOI: https://doi.org/10.1007/978-3-540-68706-1_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-68698-9
Online ISBN: 978-3-540-68706-1
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences